Skip to main content
PMC home page
Thorax logoLink to Thorax
. 2005 Apr;60(4):343–349. doi: 10.1136/thx.2004.028720

Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11–12 March 2004

M Decramer 1, R Gosselink 1, P Bartsch 1, C Lofdahl 1, W Vincken 1, R Dekhuijzen 1, J Vestbo 1, R Pauwels 1, R Naeije 1, T Troosters 1
PMCID: PMC1747377  PMID: 15790992

Abstract

During the last decade several long term studies of interventions in patients with COPD have been published. This review analyses the potential of these interventions to alter the progression of the condition. The only treatment that has unequivocally been shown to reduce the rate of decline in FEV1 is smoking cessation. Active psychological intervention in combination with pharmacotherapy is required. Other treatments may have an effect on the rate of decline in FEV1 but this appears to be very small, at most. Several treatments affect the exacerbation rate and therefore might affect the progression of the disease. Further studies are warranted to examine this effect.

Full Text

The Full Text of this article is available as a PDF (119.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aaron S. D., Kottachchi D., Ferris W. J., Vandemheen K. L., St Denis M. L., Plouffe A., Doucette S. P., Saginur R., Chan F. T., Ramotar K. Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J. 2004 Oct;24(4):631–637. doi: 10.1183/09031936.04.00049104. [DOI] [PubMed] [Google Scholar]
  2. Anthonisen Nicholas R., Connett John E., Murray Robert P. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002 Sep 1;166(5):675–679. doi: 10.1164/rccm.2112096. [DOI] [PubMed] [Google Scholar]
  3. Bendstrup K. E., Ingemann Jensen J., Holm S., Bengtsson B. Out-patient rehabilitation improves activities of daily living, quality of life and exercise tolerance in chronic obstructive pulmonary disease. Eur Respir J. 1997 Dec;10(12):2801–2806. doi: 10.1183/09031936.97.10122801. [DOI] [PubMed] [Google Scholar]
  4. Bestall J. C., Paul E. A., Garrod R., Garnham R., Jones R. W., Wedzicha A. J. Longitudinal trends in exercise capacity and health status after pulmonary rehabilitation in patients with COPD. Respir Med. 2003 Feb;97(2):173–180. doi: 10.1053/rmed.2003.1397. [DOI] [PubMed] [Google Scholar]
  5. Bourbeau J., Rouleau M. Y., Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax. 1998 Jun;53(6):477–482. doi: 10.1136/thx.53.6.477. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bourbeau Jean, Julien Marcel, Maltais François, Rouleau Michel, Beaupré Alain, Bégin Raymond, Renzi Paolo, Nault Diane, Borycki Elizabeth, Schwartzman Kevin. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003 Mar 10;163(5):585–591. doi: 10.1001/archinte.163.5.585. [DOI] [PubMed] [Google Scholar]
  7. Boyd G., Morice A. H., Pounsford J. C., Siebert M., Peslis N., Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J. 1997 Apr;10(4):815–821. [PubMed] [Google Scholar]
  8. Burge P. S., Calverley P. M., Jones P. W., Spencer S., Anderson J. A., Maslen T. K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000 May 13;320(7245):1297–1303. doi: 10.1136/bmj.320.7245.1297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Calverley P. M., Boonsawat W., Cseke Z., Zhong N., Peterson S., Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003 Dec;22(6):912–919. doi: 10.1183/09031936.03.00027003. [DOI] [PubMed] [Google Scholar]
  10. Calverley Peter, Pauwels Romain, Vestbo Jørgen, Jones Paul, Pride Neil, Gulsvik Amund, Anderson Julie, Maden Claire, TRial of Inhaled STeroids ANd long-acting beta2 agonists study group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003 Feb 8;361(9356):449–456. doi: 10.1016/S0140-6736(03)12459-2. [DOI] [PubMed] [Google Scholar]
  11. Casaburi R., Mahler D. A., Jones P. W., Wanner A., San Pedro G., ZuWallack R. L., Menjoge S. S., Serby C. W., Witek T., Jr A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002 Feb;19(2):217–224. doi: 10.1183/09031936.02.00269802. [DOI] [PubMed] [Google Scholar]
  12. Connett J. E., Kusek J. W., Bailey W. C., O'Hara P., Wu M. Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. Control Clin Trials. 1993 Apr;14(2 Suppl):3S–19S. doi: 10.1016/0197-2456(93)90021-5. [DOI] [PubMed] [Google Scholar]
  13. Connett John E., Murray Robert P., Buist A. Sonia, Wise Robert A., Bailey William C., Lindgren Paula G., Owens Gregory R., Lung Health Study Research Group Changes in smoking status affect women more than men: results of the Lung Health Study. Am J Epidemiol. 2003 Jun 1;157(11):973–979. doi: 10.1093/aje/kwg083. [DOI] [PubMed] [Google Scholar]
  14. Dahl R., Greefhorst L. A., Nowak D., Nonikov V., Byrne A. M., Thomson M. H., Till D., Della Cioppa G., Formoterol in Chronic Obstructive Pulmonary Disease I Study Group Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Sep 1;164(5):778–784. doi: 10.1164/ajrccm.164.5.2007006. [DOI] [PubMed] [Google Scholar]
  15. Decramer M., Dekhuijzen P. N., Troosters T., van Herwaarden C., Rutten-van Mölken M., van Schayck C. P., Olivieri D., Lankhorst I., Ardia A. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee. Eur Respir J. 2001 Mar;17(3):329–336. doi: 10.1183/09031936.01.17303290. [DOI] [PubMed] [Google Scholar]
  16. Decramer M., Gosselink R., Bartsch P., Löfdahl C-G, Vincken W., Dekhuijzen R., Vestbo J., Pauwels R., Naeije R., Troosters T. Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax. 2005 Apr;60(4):343–349. doi: 10.1136/thx.2004.028720. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Dekhuijzen P. N. R. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J. 2004 Apr;23(4):629–636. doi: 10.1183/09031936.04.00016804. [DOI] [PubMed] [Google Scholar]
  18. Dekhuijzen P. N., Aben K. K., Dekker I., Aarts L. P., Wielders P. L., van Herwaarden C. L., Bast A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Sep;154(3 Pt 1):813–816. doi: 10.1164/ajrccm.154.3.8810624. [DOI] [PubMed] [Google Scholar]
  19. Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. BMJ. 1994 Oct 8;309(6959):901–911. doi: 10.1136/bmj.309.6959.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Donaldson G. C., Seemungal T. A. R., Bhowmik A., Wedzicha J. A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002 Oct;57(10):847–852. doi: 10.1136/thorax.57.10.847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dowling R. B., Johnson M., Cole P. J., Wilson R. Effect of fluticasone propionate and salmeterol on Pseudomonas aeruginosa infection of the respiratory mucosa in vitro. Eur Respir J. 1999 Aug;14(2):363–369. doi: 10.1034/j.1399-3003.1999.14b21.x. [DOI] [PubMed] [Google Scholar]
  22. Dowling R. B., Rayner C. F., Rutman A., Jackson A. D., Kanthakumar K., Dewar A., Taylor G. W., Cole P. J., Johnson M., Wilson R. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa. Am J Respir Crit Care Med. 1997 Jan;155(1):327–336. doi: 10.1164/ajrccm.155.1.9001332. [DOI] [PubMed] [Google Scholar]
  23. Erjefält I., Persson C. G. Pharmacologic control of plasma exudation into tracheobronchial airways. Am Rev Respir Dis. 1991 May;143(5 Pt 1):1008–1014. doi: 10.1164/ajrccm/143.5_Pt_1.1008. [DOI] [PubMed] [Google Scholar]
  24. Garcia-Aymerich J., Farrero E., Félez M. A., Izquierdo J., Marrades R. M., Antó J. M., Estudi del Factors de Risc d'Agudització de la MPOC investigators Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax. 2003 Feb;58(2):100–105. doi: 10.1136/thorax.58.2.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Grandjean E. M., Berthet P., Ruffmann R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther. 2000 Feb;22(2):209–221. doi: 10.1016/S0149-2918(00)88479-9. [DOI] [PubMed] [Google Scholar]
  26. Griffiths T. L., Burr M. L., Campbell I. A., Lewis-Jenkins V., Mullins J., Shiels K., Turner-Lawlor P. J., Payne N., Newcombe R. G., Ionescu A. A. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000 Jan 29;355(9201):362–368. doi: 10.1016/s0140-6736(99)07042-7. [DOI] [PubMed] [Google Scholar]
  27. Güell R., Casan P., Belda J., Sangenis M., Morante F., Guyatt G. H., Sanchis J. Long-term effects of outpatient rehabilitation of COPD: A randomized trial. Chest. 2000 Apr;117(4):976–983. doi: 10.1378/chest.117.4.976. [DOI] [PubMed] [Google Scholar]
  28. Highland Kristin B., Strange Charlie, Heffner John E. Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med. 2003 Jun 17;138(12):969–973. doi: 10.7326/0003-4819-138-12-200306170-00008. [DOI] [PubMed] [Google Scholar]
  29. Jones P. W., Bosh T. K. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997 Apr;155(4):1283–1289. doi: 10.1164/ajrccm.155.4.9105068. [DOI] [PubMed] [Google Scholar]
  30. Kanner R. E., Anthonisen N. R., Connett J. E., Lung Health Study Research Group Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001 Aug 1;164(3):358–364. doi: 10.1164/ajrccm.164.3.2010017. [DOI] [PubMed] [Google Scholar]
  31. Kanner R. E., Connett J. E., Williams D. E., Buist A. S. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med. 1999 Apr;106(4):410–416. doi: 10.1016/s0002-9343(99)00056-x. [DOI] [PubMed] [Google Scholar]
  32. Kerstjens H. A., Brand P. L., Hughes M. D., Robinson N. J., Postma D. S., Sluiter H. J., Bleecker E. R., Dekhuijzen P. N., de Jong P. M., Mengelers H. J. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. N Engl J Med. 1992 Nov 12;327(20):1413–1419. doi: 10.1056/NEJM199211123272003. [DOI] [PubMed] [Google Scholar]
  33. Korn S. H., Jerre A., Brattsand R. Effects of formoterol and budesonide on GM-CSF and IL-8 secretion by triggered human bronchial epithelial cells. Eur Respir J. 2001 Jun;17(6):1070–1077. doi: 10.1183/09031936.01.00073301. [DOI] [PubMed] [Google Scholar]
  34. Lacasse Y., Brosseau L., Milne S., Martin S., Wong E., Guyatt G. H., Goldstein R. S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(3):CD003793–CD003793. doi: 10.1002/14651858.CD003793. [DOI] [PubMed] [Google Scholar]
  35. Lacasse Y., Guyatt G. H., Goldstein R. S. The components of a respiratory rehabilitation program: a systematic overview. Chest. 1997 Apr;111(4):1077–1088. doi: 10.1378/chest.111.4.1077. [DOI] [PubMed] [Google Scholar]
  36. Liesker J. J. W., Van De Velde V., Meysman M., Vincken W., Wollmer Per, Hansson L., Kerstjens H. A. M., Qvint U., Pauwels R. A. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med. 2002 Aug;96(8):559–566. doi: 10.1053/rmed.2001.1335. [DOI] [PubMed] [Google Scholar]
  37. Macnee W., Rahman I. Oxidants and antioxidants as therapeutic targets in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Nov;160(5 Pt 2):S58–S65. doi: 10.1164/ajrccm.160.supplement_1.15. [DOI] [PubMed] [Google Scholar]
  38. Mahler D. A., Donohue J. F., Barbee R. A., Goldman M. D., Gross N. J., Wisniewski M. E., Yancey S. W., Zakes B. A., Rickard K. A., Anderson W. H. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999 Apr;115(4):957–965. doi: 10.1378/chest.115.4.957. [DOI] [PubMed] [Google Scholar]
  39. Maltais F., LeBlanc P., Simard C., Jobin J., Bérubé C., Bruneau J., Carrier L., Belleau R. Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):442–447. doi: 10.1164/ajrccm.154.2.8756820. [DOI] [PubMed] [Google Scholar]
  40. Mannino D. M., Gagnon R. C., Petty T. L., Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000 Jun 12;160(11):1683–1689. doi: 10.1001/archinte.160.11.1683. [DOI] [PubMed] [Google Scholar]
  41. Murray R. P., Anthonisen N. R., Connett J. E., Wise R. A., Lindgren P. G., Greene P. G., Nides M. A. Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. J Clin Epidemiol. 1998 Dec;51(12):1317–1326. doi: 10.1016/s0895-4356(98)00120-6. [DOI] [PubMed] [Google Scholar]
  42. Murray R. P., Bailey W. C., Daniels K., Bjornson W. M., Kurnow K., Connett J. E., Nides M. A., Kiley J. P. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996 Feb;109(2):438–445. doi: 10.1378/chest.109.2.438. [DOI] [PubMed] [Google Scholar]
  43. O'Donnell D. E., McGuire M., Samis L., Webb K. A. General exercise training improves ventilatory and peripheral muscle strength and endurance in chronic airflow limitation. Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1489–1497. doi: 10.1164/ajrccm.157.5.9708010. [DOI] [PubMed] [Google Scholar]
  44. O'Hara P., Grill J., Rigdon M. A., Connett J. E., Lauger G. A., Johnston J. J. Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Prev Med. 1993 May;22(3):304–315. doi: 10.1006/pmed.1993.1025. [DOI] [PubMed] [Google Scholar]
  45. Oostenbrink J. B., Rutten-van Mölken M. P. M. H., Al M. J., Van Noord J. A., Vincken W. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J. 2004 Feb;23(2):241–249. doi: 10.1183/09031936.03.00083703. [DOI] [PubMed] [Google Scholar]
  46. Pauwels R. A., Löfdahl C. G., Laitinen L. A., Schouten J. P., Postma D. S., Pride N. B., Ohlsson S. V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948–1953. doi: 10.1056/NEJM199906243402503. [DOI] [PubMed] [Google Scholar]
  47. Pinto-Plata V. M., Cote C., Cabral H., Taylor J., Celli B. R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004 Jan;23(1):28–33. doi: 10.1183/09031936.03.00034603. [DOI] [PubMed] [Google Scholar]
  48. Poole P. J., Black P. N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. BMJ. 2001 May 26;322(7297):1271–1274. doi: 10.1136/bmj.322.7297.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Redelmeier D. A., Bayoumi A. M., Goldstein R. S., Guyatt G. H. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am J Respir Crit Care Med. 1997 Apr;155(4):1278–1282. doi: 10.1164/ajrccm.155.4.9105067. [DOI] [PubMed] [Google Scholar]
  50. Reid M. B. COPD as a muscle disease. Am J Respir Crit Care Med. 2001 Oct 1;164(7):1101–1102. doi: 10.1164/ajrccm.164.7.2108039a. [DOI] [PubMed] [Google Scholar]
  51. Renkema T. E., Schouten J. P., Koëter G. H., Postma D. S. Effects of long-term treatment with corticosteroids in COPD. Chest. 1996 May;109(5):1156–1162. doi: 10.1378/chest.109.5.1156. [DOI] [PubMed] [Google Scholar]
  52. Rennard S., Decramer M., Calverley P. M. A., Pride N. B., Soriano J. B., Vermeire P. A., Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 2002 Oct;20(4):799–805. doi: 10.1183/09031936.02.03242002. [DOI] [PubMed] [Google Scholar]
  53. Repine J. E., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):341–357. doi: 10.1164/ajrccm.156.2.9611013. [DOI] [PubMed] [Google Scholar]
  54. Ries A. L., Kaplan R. M., Limberg T. M., Prewitt L. M. Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995 Jun 1;122(11):823–832. doi: 10.7326/0003-4819-122-11-199506010-00003. [DOI] [PubMed] [Google Scholar]
  55. Ries Andrew L., Kaplan Robert M., Myers Roseann, Prewitt Lela M. Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med. 2002 Dec 27;167(6):880–888. doi: 10.1164/rccm.200204-318OC. [DOI] [PubMed] [Google Scholar]
  56. Sala E., Roca J., Marrades R. M., Alonso J., Gonzalez De Suso J. M., Moreno A., Barberá J. A., Nadal J., de Jover L., Rodriguez-Roisin R. Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999 Jun;159(6):1726–1734. doi: 10.1164/ajrccm.159.6.9804136. [DOI] [PubMed] [Google Scholar]
  57. Salman Ghassan F., Mosier Michael C., Beasley Brent W., Calkins David R. Rehabilitation for patients with chronic obstructive pulmonary disease: meta-analysis of randomized controlled trials. J Gen Intern Med. 2003 Mar;18(3):213–221. doi: 10.1046/j.1525-1497.2003.20221.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Sin Don D., McAlister Finlay A., Man S. F. Paul, Anthonisen Nick R. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA. 2003 Nov 5;290(17):2301–2312. doi: 10.1001/jama.290.17.2301. [DOI] [PubMed] [Google Scholar]
  59. Soriano J. B., Vestbo J., Pride N. B., Kiri V., Maden C., Maier W. C. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J. 2002 Oct;20(4):819–825. doi: 10.1183/09031936.02.00301302. [DOI] [PubMed] [Google Scholar]
  60. Spencer S., Calverley P. M. A., Burge P. S., Jones P. W. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698–702. doi: 10.1183/09031936.04.00121404. [DOI] [PubMed] [Google Scholar]
  61. Spencer S., Calverley P. M., Sherwood Burge P., Jones P. W., ISOLDE Study Group. Inhaled Steroids in Obstructive Lung Disease Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001 Jan;163(1):122–128. doi: 10.1164/ajrccm.163.1.2005009. [DOI] [PubMed] [Google Scholar]
  62. Spencer S., Jones P. W., GLOBE Study Group Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax. 2003 Jul;58(7):589–593. doi: 10.1136/thorax.58.7.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Spruit M. A., Gosselink R., Troosters T., Kasran A., Gayan-Ramirez G., Bogaerts P., Bouillon R., Decramer M. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003 Sep;58(9):752–756. doi: 10.1136/thorax.58.9.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Stey C., Steurer J., Bachmann S., Medici T. C., Tramèr M. R. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J. 2000 Aug;16(2):253–262. doi: 10.1034/j.1399-3003.2000.16b12.x. [DOI] [PubMed] [Google Scholar]
  65. Sutherland E. R., Allmers H., Ayas N. T., Venn A. J., Martin R. J. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003 Nov;58(11):937–941. doi: 10.1136/thorax.58.11.937. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Swerts P. M., Kretzers L. M., Terpstra-Lindeman E., Verstappen F. T., Wouters E. F. Exercise reconditioning in the rehabilitation of patients with chronic obstructive pulmonary disease: a short- and long-term analysis. Arch Phys Med Rehabil. 1990 Jul;71(8):570–573. [PubMed] [Google Scholar]
  67. Szafranski W., Cukier A., Ramirez A., Menga G., Sansores R., Nahabedian S., Peterson S., Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003 Jan;21(1):74–81. doi: 10.1183/09031936.03.00031402. [DOI] [PubMed] [Google Scholar]
  68. Timms R. M., Khaja F. U., Williams G. W. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med. 1985 Jan;102(1):29–36. doi: 10.7326/0003-4819-102-1-29. [DOI] [PubMed] [Google Scholar]
  69. Troosters T., Gosselink R., Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med. 2000 Aug 15;109(3):207–212. doi: 10.1016/s0002-9343(00)00472-1. [DOI] [PubMed] [Google Scholar]
  70. Vestbo J., Sørensen T., Lange P., Brix A., Torre P., Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999 May 29;353(9167):1819–1823. doi: 10.1016/s0140-6736(98)10019-3. [DOI] [PubMed] [Google Scholar]
  71. Vincken W., van Noord J. A., Greefhorst A. P. M., Bantje Th A., Kesten S., Korducki L., Cornelissen P. J. G., Dutch/Belgian Tiotropium Study Group Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002 Feb;19(2):209–216. doi: 10.1183/09031936.02.00238702. [DOI] [PubMed] [Google Scholar]
  72. Wadbo M., Löfdahl C. G., Larsson K., Skoogh B. E., Tornling G., Arweström E., Bengtsson T., Ström K., Swedish Society of Respiratory Medicine Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J. 2002 Nov;20(5):1138–1146. doi: 10.1183/09031936.02.00301702. [DOI] [PubMed] [Google Scholar]
  73. Weir D. C., Bale G. A., Bright P., Sherwood Burge P. A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease. Clin Exp Allergy. 1999 Jun;29 (Suppl 2):125–128. doi: 10.1046/j.1365-2222.1999.00021.x. [DOI] [PubMed] [Google Scholar]
  74. Wise Robert A., Kanner Richard E., Lindgren Paula, Connett John E., Altose Murray D., Enright Paul L., Tashkin Donald P., Lung Health Study Research Group The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: the Lung Health Study. Chest. 2003 Aug;124(2):449–458. doi: 10.1378/chest.124.2.449. [DOI] [PubMed] [Google Scholar]
  75. van Grunsven P. M., van Schayck C. P., Derenne J. P., Kerstjens H. A., Renkema T. E., Postma D. S., Similowski T., Akkermans R. P., Pasker-de Jong P. C., Dekhuijzen P. N. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 1999 Jan;54(1):7–14. doi: 10.1136/thx.54.1.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. van Schayck C. P., Dompeling E., van Herwaarden C. L., Folgering H., Akkermans R. P., van den Broek P. J., van Weel C. Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized controlled study. Br J Gen Pract. 1995 May;45(394):239–244. [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES